Lacosamid-i.v.-Register (LCM)
![]() |
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. |
ClinicalTrials.gov Identifier: NCT01620840 |
Recruitment Status :
Completed
First Posted : June 15, 2012
Last Update Posted : May 28, 2015
|
Sponsor:
University Hospital Schleswig-Holstein
Information provided by (Responsible Party):
Ulrich Stephani, University Hospital Schleswig-Holstein
Tracking Information | ||||
---|---|---|---|---|
First Submitted Date | June 13, 2012 | |||
First Posted Date | June 15, 2012 | |||
Last Update Posted Date | May 28, 2015 | |||
Study Start Date | June 2011 | |||
Actual Primary Completion Date | November 2013 (Final data collection date for primary outcome measure) | |||
Current Primary Outcome Measures | Not Provided | |||
Original Primary Outcome Measures | Not Provided | |||
Change History | ||||
Current Secondary Outcome Measures | Not Provided | |||
Original Secondary Outcome Measures | Not Provided | |||
Current Other Pre-specified Outcome Measures | Not Provided | |||
Original Other Pre-specified Outcome Measures | Not Provided | |||
Descriptive Information | ||||
Brief Title | Lacosamid-i.v.-Register | |||
Official Title | Lacosamid-i.v.-Register | |||
Brief Summary | Lacosamide is a new antiepileptic drug (AED) marketed as Vimpat with three different formulations, tablets, oral syrup and a solution for intravenous infusion. Lacosamide is approved as adjunctive therapy in epilepsy patients with partial onset seizures with or without secondary generalization. The i.v. solution is used in patients in which oral administration is not possible or adequate. Bioequivalence with oral tablets and safety could be demonstrated in healthy volunteers and in patients switched from tablets to Lacosamide i.v. solution. A recently published study demonstrates the feasibility of single loading doses up to 300 mg. The aim of this Lacosamide i.v. registry is to collect systematically data on the safety, tolerability and administration procedures when Lacosmide i.v. is used in routine daily clinical practice, mainly in hospitals. These data will help treating physicians to optimize the use of Lacosamide i.v. in clinical routine. | |||
Detailed Description | Not Provided | |||
Study Type | Observational | |||
Study Design | Observational Model: Case-Only Time Perspective: Prospective |
|||
Target Follow-Up Duration | Not Provided | |||
Biospecimen | Not Provided | |||
Sampling Method | Non-Probability Sample | |||
Study Population | Patients who are treated with Lacosamide i.v.-solution in routine clinical practice. | |||
Condition | Epilepsy With Partial Onset Seizures With or Without Secondary Generalization | |||
Intervention | Drug: Lacosamide 10mg/ml
intravenous administration up to 10 days
Other Name: VimpatⓇ
|
|||
Study Groups/Cohorts | Lacosamid-i.v. treatment
Intervention: Drug: Lacosamide 10mg/ml
|
|||
Publications * | Not Provided | |||
* Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline. |
||||
Recruitment Information | ||||
Recruitment Status | Completed | |||
Actual Enrollment |
130 | |||
Original Estimated Enrollment |
200 | |||
Actual Study Completion Date | November 2013 | |||
Actual Primary Completion Date | November 2013 (Final data collection date for primary outcome measure) | |||
Eligibility Criteria | Inclusion Criteria:
Exclusion Criteria: |
|||
Sex/Gender |
|
|||
Ages | 18 Years and older (Adult, Older Adult) | |||
Accepts Healthy Volunteers | No | |||
Contacts | Contact information is only displayed when the study is recruiting subjects | |||
Listed Location Countries | Germany | |||
Removed Location Countries | ||||
Administrative Information | ||||
NCT Number | NCT01620840 | |||
Other Study ID Numbers | UCB-LCM-2011 | |||
Has Data Monitoring Committee | Yes | |||
U.S. FDA-regulated Product | Not Provided | |||
IPD Sharing Statement | Not Provided | |||
Responsible Party | Ulrich Stephani, University Hospital Schleswig-Holstein | |||
Study Sponsor | University Hospital Schleswig-Holstein | |||
Collaborators | Not Provided | |||
Investigators |
|
|||
PRS Account | University Hospital Schleswig-Holstein | |||
Verification Date | May 2015 |